Evidence map›Paper›PMID 33544718›Full record

ArticlePLoS computational biology2021

Modeling drug response using network-based personalized treatment prediction (NetPTP) with applications to inflammatory bowel disease.

Lichy Han, Zahra N Sayyid, Russ B Altman

Open access · goldAbstract read
In one paragraph

Article in PLoS computational biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Lichy HanBiomedical Informatics Training Program, Stanford University, Stanford, California, United States of America.
Zahra N SayyidDepartment of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, California, United States of America.ORCID 0000-0001-6872-7028
Russ B AltmanDepartment of Genetics, Stanford University, Stanford, California, United States of America.ORCID 0000-0003-3859-2905
Stanford University · US

Funding

PharmGKB: pharmacogenomics discovery and implementationU24HG010615 · NHGRI · STANFORD UNIVERSITY · PI TERI Ellen KLEIN, Michelle Whirl-Carrillo · 2020 to 2026
$9.5M
Undergraduate Summer Research Experiences Support for Combining systems biology and structural biology to find new therapeuticsR01GM102365 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO · 2012 to 2021
$3.0M
Systems Pharmacological Analysis of Drug Efficacy in Inflammatory Bowel DiseaseF30AI124553 · NIAID · STANFORD UNIVERSITY · PI HAN, LICHY · 2017 to 2019
$120k
NHGRI NIH HHS U24 HG010615NIAID NIH HHS F30 AI124553NIGMS NIH HHS R01 GM102365
6 · The paper itself

Abstract

For many prevalent complex diseases, treatment regimens are frequently ineffective. For example, despite multiple available immunomodulators and immunosuppressants, inflammatory bowel disease (IBD) remains difficult to treat. Heterogeneity in the disease across patients makes it challenging to select the optimal treatment regimens, and some patients do not respond to any of the existing treatment choices. Drug repurposing strategies for IBD have had limited clinical success and have not typically offered individualized patient-level treatment recommendations. In this work, we present NetPTP, a Network-based Personalized Treatment Prediction framework which models measured drug effects from gene expression data and applies them to patient samples to generate personalized ranked treatment lists. To accomplish this, we combine publicly available network, drug target, and drug effect data to generate treatment rankings using patient data. These ranked lists can then be used to prioritize existing treatments and discover new therapies for individual patients. We demonstrate how NetPTP captures and models drug effects, and we apply our framework to individual IBD samples to provide novel insights into IBD treatment.

Indexed as

AlgorithmsAnimalsDatabases, FactualDrug DesignDrug RepositioningGene Expression ProfilingHumansImmunosuppressive AgentsInflammatory Bowel DiseasesMicePhylogenyPrecision MedicineImmunosuppressive Agents

Identifiers

PMID33544718
PMCPMC7891788
OpenAlexW3127705983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.